UniProtKB/SwissProt variant VAR

Variant information

Variant position:

338

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

LB/B

The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Glycine (G) to Valine (V) at position 338 (G338V, p.Gly338Val).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Change from glycine (G) to medium size and hydrophobic (V)

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

-3

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Sequence information

Variant position:

338

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

391

The length of the canonical sequence.

Location on the sequence:

HVPPAGQGSYSAPTLTGMVP G SEFSGSPYSHPQYSSYNDSW

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         HVPPAGQGSYSAPTLTGMVPGSEFSGSPYSHPQYSSYNDSW

Mouse                         HVPPAGQGSYSAPTLTGMVPGSEFSGSPYSHPQYSSYNDSW

Xenopus laevis                HVPPAGQGSYSAPTLTGMVPGSDFSGSPYSHPQYSSYNDSW

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 391	Paired box protein Pax-5
Alternative sequence	261 – 391	TTEYSAMASLAGGLDDMKANLASPTPADIGSSVPGPQSYPIVTGRDLASTTLPGYPPHVPPAGQGSYSAPTLTGMVPGSEFSGSPYSHPQYSSYNDSWRFPNPGLLGSPYYYSAAARGAAPPAAATAYDRH -> AVTWRARPSPGTLHTSPPLDRAATQHRR. In isoform 5.
Alternative sequence	304 – 366	Missing. In isoform 7.
Alternative sequence	305 – 349	RDLASTTLPGYPPHVPPAGQGSYSAPTLTGMVPGSEFSGSPYSHP -> SEFSGSPYSHP. In isoform 6.
Alternative sequence	308 – 391	Missing. In isoform 11.
Alternative sequence	319 – 391	VPPAGQGSYSAPTLTGMVPGSEFSGSPYSHPQYSSYNDSWRFPNPGLLGSPYYYSAAARGAAPPAAATAYDRH -> LQPPLPMTVTDPWSQAGTKH. In isoform 3 and isoform 4.
Alternative sequence	338 – 366	Missing. In isoform 2 and isoform 9.

Literature citations

A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.
Shah S.; Schrader K.A.; Waanders E.; Timms A.E.; Vijai J.; Miething C.; Wechsler J.; Yang J.; Hayes J.; Klein R.J.; Zhang J.; Wei L.; Wu G.; Rusch M.; Nagahawatte P.; Ma J.; Chen S.C.; Song G.; Cheng J.; Meyers P.; Bhojwani D.; Jhanwar S.; Maslak P.; Fleisher M.; Littman J.; Offit L.; Rau-Murthy R.; Fleischut M.H.; Corines M.; Murali R.; Gao X.; Manschreck C.; Kitzing T.; Murty V.V.; Raimondi S.C.; Kuiper R.P.; Simons A.; Schiffman J.D.; Onel K.; Plon S.E.; Wheeler D.A.; Ritter D.; Ziegler D.S.; Tucker K.; Sutton R.; Chenevix-Trench G.; Li J.; Huntsman D.G.; Hansford S.; Senz J.; Walsh T.; Lee M.; Hahn C.N.; Roberts K.G.; King M.C.; Lo S.M.; Levine R.L.; Viale A.; Socci N.D.; Nathanson K.L.; Scott H.S.; Daly M.; Lipkin S.M.; Lowe S.W.; Downing J.R.; Altshuler D.; Sandlund J.T.; Horwitz M.S.; Mullighan C.G.; Offit K.;
Nat. Genet. 45:1226-1231(2013)
Cited for: VARIANT ALL3 SER-183; VARIANTS ARG-24; GLY-26; GLN-34; VAL-53; GLY-59; ASN-66; ARG-75; ARG-80; THR-139; ILE-151; VAL-183; LEU-213; THR-301 AND VAL-338; CHARACTERIZATION OF VARIANT ALL3 SER-183;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q02548: Variant p.Gly338Val